Download PDF
Horm Metab Res 2002; 34(5): 245-249
DOI: 10.1055/s-2002-32137
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Atrial Natriuretic Hormone, Vessel Dilator, Long Acting Natriuretic Hormone, and Kaliuretic Hormone Decrease Circulating Prolactin Concentrations

D.  L.  Vesely 1, 2, 3 , G.  I.  San Miguel 1, 2, 3 , I.  Hassan1, 2, 3 , D.  D.  Schocken1, 2
  • 1University of South Florida Cardiac Hormone Center, Tampa, USA
  • 2Departments of Internal Medicine, Physiology and Biophysics, University of South Florida Health Sciences Center, Tampa, USA
  • 3James A. Haley Veterans Medical Center, Tampa, USA
Further Information

Publication History

1 August 2001

9 January 2002

Publication Date:
10 June 2002 (online)

Also available at
    Permissions and Reprints

Abstract

The present investigation was designed to test whether four cardiac hormones - long acting natriuretic hormone, vessel dilator, kaliuretic hormone and atrial natriuretic hormone decrease the circulating concentration of prolactin in humans (n = 30). Vessel dilator, kaliuretic hormone, long acting natriuretic hormone and atrial natriuretic hormone decreased the circulating concentration of prolactin to 3 %, 31 %, 27 %, and 23 % of control values, respectively, at the end of their infusions when infused at concentrations of 100 ng/kg body weight per minute for 60 minutes (p < 0.001 for each). Vessel dilator, kaliuretic hormone, long acting natriuretic hormone and atrial natriuretic hormone had sustained effects on modulating prolactin’s concentrations, with circulating concentrations of 1 %, 64 %, 28 %, and 2 % of control values (p < 0.001) 3 hours after stopping their respective infusions. These results suggest that there are four circulating prolactin-inhibitory hormones in addition to the hypothalamic mediators, dopamine and corticotropin-releasing hormone, which modulate prolactin release. These peptide hormones’ ability to decrease circulating prolactin concentrations may be mediated in part by dopamine and in part by their demonstrated ability to decrease corticotropin-releasing hormone concentrations, which stimulate prolactin release.

Key words

Prolactin-Inhibitory Hormones - Corticotropin-Releasing Hormone - Hypothalamus - Natriuretic Hormones

References

  • 1 Ohashi M, Fujio N, Nawata H, Kato K, Matsuo H, Ibayashi H. Effect of α-human atrial natriuretic polypeptide on anterior pituitary function in men.  Endocr J. 1987;  34 659-663
    PubMedGoogle Scholar
  • 2 Foresta C, Caretto A, Mioni R, Betterle C, Scandellari C. Evidence of immunoreactive human atrial peptides in human anterior pituitary cells.  Horm Metab Res. 1988;  20 376-377
    PubMedGoogle Scholar
  • 3 Foresta C, DeCarlo E, Mioni R, Zorzi M, Scandellari C. Evidence for a dopaminergic involvement in the inhibitory effect of alpha human natriuretic peptide on prolactin in man.  Horm Metab Res. 1989;  21 630-634
    PubMedGoogle Scholar
  • 4 Wiedemann K, Herzog L, Kellner M. Atrial natriuretic hormone inhibits corticotropin-releasing hormone-induced prolactin release in man.  J Psychr Res. 1995;  29 51-58
    CrossrefPubMedGoogle Scholar
  • 5 Vesely D L. Atrial Natriuretic Hormones. Englewood Cliffs Prentice Hall.  1992;  1-256
    PubMedGoogle Scholar
  • 6 Standaert D G, Needleman P, Day M L, Weigand R, Krause J E. Expression of the gene for preproatriopeptin in the central nervous system of the rat.  Mol Brain Res. 1988;  4 7-13
    CrossrefPubMedGoogle Scholar
  • 7 Martin D R, Pevahouse J B, Trigg D J, Vesely D L, Buerkert J E. Three peptides from the ANF prohormone NH2-terminuteus are natriuretic and/or kaliuretic.  Am J Physiol. 1990;  258 F1401-F1408
    PubMedGoogle Scholar
  • 8 Vesely D L, Norris J S, Walters J M, Jespersen R R, Baeyens D A. Atrial natriuretic prohormone peptides 1 - 30, 31 - 67 and 79 - 98 vasodilate the aorta.  Biochem Biophys Res Commun. 1987;  148 1540-1548
    CrossrefPubMedGoogle Scholar
  • 9 Vesely D L, Douglass M A, Dietz J R, Giordano A T, McCormick M T, Rodriguez-Paz G, Schocken D D. Negative feedback of atrial natriuretic peptides.  J Clin Endocrinol Metab. 1994;  78 1128-1134
    CrossrefPubMedGoogle Scholar
  • 10 Vesely D L, Douglass M A, Dietz J R, Gower W R , McCormick M T, Rodriguez-Paz G, Schocken D D. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce a diuresis, natriuresis, and/or kaliuresis in humans.  Circulation. 1994;  90 1129-1140
    PubMedGoogle Scholar
  • 11 Vesely D L, Dietz J R, Parks J R, Baig M, McCormick M T, Cintron G, Schocken D D. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure.  Circulation. 1998;  98 323-329
    PubMedGoogle Scholar
  • 12 Vesely D L, Norsk P, Winters C J, Rico D M, Sallman A L, Epstein M. Increased release of the N-terminal and C -terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans.  Proc Soc Exp Biol Med. 1989;  192 230-235
    PubMedGoogle Scholar
  • 13 Winters C J, Sallman A L, Baker B J, Meadows J, Rico D M, Vesely D L. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure.  Circulation. 1989;  80 438-449
    PubMedGoogle Scholar
  • 14 Hunter E FM, Kelly P A, Prowse C, Woods R J, Lowry P J. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease.  Scan J Clin Lab Invest. 1998;  58 205-216
    PubMedGoogle Scholar
  • 15 Ackerman B H, Wyeth R P, Vesely D L, Ngo L, Bissett J K, Winters C H, Sallman A L. Pharmacokinetic characterization of the post-distribution phase of prohormone atrial natriuretic peptides amino acids 1 - 98, 31 - 67, and atrial natriuretic factor during and following rapid right ventricular pacing in dogs.  J Clin Pharmacol. 1992;  32 415-421
    PubMedGoogle Scholar
  • 16 Poulos J E, Gower W R, Sullebarger J T, Fontanet H L, Vesely D L. Congestive heart failure: Increased cardiac and extracardiac atrial natriuretic peptide gene expression.  Cardiovasc Res. 1996;  32 909-919
    CrossrefPubMedGoogle Scholar
  • 17 Dietz J R, Nazian S J, Vesely D L. Release of ANF, proANF 1 - 98, and proANF 31 - 67 from isolated rat atria by atrial distention.  Am J Physiol. 1991;  260 H1774-H1778
    PubMedGoogle Scholar
  • 18 Ackerman B H, Overton R M, McCormick M T, Schocken D D, Vesely D L. Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans following a one-hour infusion.  J Pharmacol Exp Therap. 1997;  282 603-608
    PubMedGoogle Scholar
  • 19 Schulte H M, Chrousos G P, Gold P W, Oldfield E H, Hoban M C, Cutler G B, Loriaux D L. Corticotropin-releasing factor (CRF): A common link between anterior pituitary and sympathetic responses to stress.  Acta Endocrinol. 1983;  102 (Suppl 253) 32-33
    PubMedGoogle Scholar
  • 20 Vesely D L, San Miguel G I, Hassan I, Schocken D D. Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of corticotropin-releasing hormone, corticotropin and cortisol.  J Clin Endocrinol Metab. 2001;  86 4244-4249
    CrossrefPubMedGoogle Scholar
  • 21 Flores C M, Hulihan-Giblin G A, Homby P J, Lumpkin M D, Kellar K J. Partial characterization of the neurotransmitter pathway regulating the in vitro release of prolactin.  Neuroendocrinology. 1992;  55 519-528
    PubMedGoogle Scholar
  • 22 Sampson W K, Bianchi R. Further evidence for a hypothalamic site of action of atrial natriuretic factor: inhibition of prolactin secretion in the conscious rat.  Can J Physiol Pharmacol. 1988;  66 301-305
    PubMedGoogle Scholar
  • 23 Sampson W K, Bianchi R, Mogg R. Evidence for a dopaminergic mechanism for the prolactin inhibitory effect of atrial natriuretic factor.  Neuroendocrinology. 1988;  47 268-271
    PubMedGoogle Scholar
  • 24 Kadowaki K, Hirota K, Koike K, Ohmichi M, Miyake A, Tanizawa O. Atrial and brain natriuretic peptides enhance dopamine accumulation in cultured hypothalamic cells including dopaminergic neurons.  Neuroendocrinology. 1992;  56 11-17
    PubMedGoogle Scholar
  • 25 Nakao K, Katsura G, Mori N, Itoh H, Shiono S, Yamada T, Sugawara A, Sakamoto M, Saito Y, Eigyo M, Matsushita A, Imura H. Inhibitory effect of centrally administered atrial natriuretic polypeptide on brain dopaminergic system in rats.  Eur J Pharmacol. 1986;  131 171-177
    CrossrefPubMedGoogle Scholar
  • 26 Kawata M, Nakao K, Morii N, Kiso Y, Yamashita H, Imura H, Sano Y. Atrial natriuretic polypeptide: Topographical distribution in the rat brain by radioimmunoassay and immunochemistry.  Neuroscience. 1985;  16 521-546
    CrossrefPubMedGoogle Scholar
  • 27 Kurihara M, Saavedra J M, Shigematsu K. Localization and characterization of atrial natriuretic peptide binding sites in discrete areas of rat brain and pituitary gland by quantitative autoradiography.  Brain Res. 1987;  408 31-39
    CrossrefPubMedGoogle Scholar
  • 28 Koch B, Boudjada T, Lutz-Bucher B. Characterization of high affinity receptor sites for atrial natriuretic factor in anterior pituitary gland: evidence for the existence of two receptor forms.  Biochem Biophys Res Commun. 1988;  152 904-909
    PubMedGoogle Scholar
  • 29 Wilcox J N, Augustine A, Goeddel D V, Lowe D G. Differential regional expression of three natriuretic peptide receptor genes within primate tissues.  Mol Cell Biol. 1991;  11 3454-3462
    PubMedGoogle Scholar
  • 30 Grandclement B, Brisson C, Bayard G, Tremblay J, Gossard F, Morel G. Localization of mRNA coding for three subtypes of atrial natriuretic factor (ANF) receptors in rat anterior pituitary gland cells.  J Neuroendocrinol. 1995;  7 939-948
    PubMedGoogle Scholar
  • 31 Gutkowska J, Antunes-Rodrigues J, McCann S M. Atrial natriuretic peptide in brain and pituitary gland.  Physiological Rev. 1997;  77 465-515
    PubMedGoogle Scholar
  • 32 Edwards A V, Ghatei M A, Bloom S R. The effect of splanchnic nerve stimulation on the uptake of atrial natriuretic peptide by the adrenal gland of conscious calves.  J Endocrinol Invest. 1990;  13 887-892
    PubMedGoogle Scholar
  • 33 Duntas L, Bornstein S R, Scherbaum W A, Holst J J. Atrial natriuretic peptide-like immunoreactive material (ANP-LI) is released from the adrenal gland by splanchnic stimulation. Exp & Clin.  Endocrinol. 1993;  101 371-373
    PubMedGoogle Scholar
  • 34 Katznelson L, Klibanski A. Prolactin and its disorders.  In: Principles and Practice of Endocrinology and Metabolism. Becker KL (ed) .Philadelphia; J B Lippincott Co. 1995: 140-147
    Google Scholar
  • 35 Vesely D L, Winters C J, Sallman A L. Prohormone atrial natriuretic peptides 1 - 30 and 31 - 67 increase in hyperthyroidism and decrease in hypothyroidism.  Am J Med Sci. 1989;  297 209-215
    PubMedGoogle Scholar
  • 36 Honbo K S, Herle A JV, Kellett K A. Serum prolactin levels in untreated primary hypothyroidism.  Am J Med. 1978;  64 782-787
    CrossrefPubMedGoogle Scholar

D. L. Vesely, M.D., Ph.D.

Chief, Endocrinology, Diabetes & Metabolism · James A. Haley Veterans Hospital-151

13000 Bruce B. Downs Blvd. · Tampa, Florida 33612 · USA ·

Phone: + 1 (813) 972-7624

Fax: + 1 (813) 972-7623

Email: vesely.david_l@tampa.va.gov